Feed AVDL
AV

Avadel Pharmaceuticals plc

AVDL · NASDAQ

$21.64 +0.00% (+$0.00)
Market Cap $2.12B
P/E Ratio -
Div. Yield -
ROE 0.33%
Piotroski F-Score Moderate
4/9
Valuation
0 /100
Expensive
EV/EBITDA 205.49x
P/S 8.55x
P/B 21.62x
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
49 /100
Moderate
Gross margin 94.47%
Net margin 0.11%
Op. margin 1.82%
Quality
16 /100
Poor
ROIC 0.28%
ROE 0.33%
ROA 0.14%
Debt
80 /100
Low
Debt/Equity 0.38x
Current ratio 2.76x
Int. coverage 0.66x
Stability
19 /100
Unstable
Beta 1.31x
EPS volatility 662.55%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre AVDL
Online

Despre companie

Avadel Pharmaceuticals plc (AVDL) is an Irish pharmaceutical company focused on the development and commercialization of medicines for the treatment of neurological and cardiovascular diseases. With a product portfolio including drugs such as FT218 and Noctiva, Avadel Pharmaceuticals aims to provide innovative therapeutic options for patients suffering from various conditions. The company emphasizes research and development of new drug formulations and treatment approaches to meet the needs of patients and the medical community. Avadel Pharmaceuticals plc (AVDL) shares could be suitable for investors looking for investments in the pharmaceutical industry with a focus on innovative therapies and drug development for neurological and cardiovascular diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Gregory J. Divis Jr.

Employees

188

Headquarters

Dublin

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.